Structural features of IgA molecules which contribute to IgA nephropathy

Area of Science:

• Nephrology
• Immunology
• Glycobiology

Background:

• IgA nephropathy (IgAN) is defined by mesangial deposition of polymeric IgA1 (pIgA1).
• The source of increased pIgA1 in IgAN patients is debated, with potential links to altered immune cell function.
• Current understanding lacks a clear mechanism for pIgA1 mesangial deposition, suggesting non-immune complex pathways.

Purpose of the Study:

• To investigate the role of altered glycosylation in IgA nephropathy pathogenesis.
• To explore the potential impact of physicochemical abnormalities in IgA1 on mesangial deposition.
• To determine if altered O-glycosylation of IgA1 contributes to glomerular injury in IgAN.

Main Methods:

• Analysis of IgA1 glycosylation patterns in circulating IgA1 from IgAN patients.
• Focus on O-glycosylation in the distinctive hinge region of IgA1.
• Exploration of potential defects in enzymes like beta1,3 galactosyltransferase involved in glycosylation.

Main Results:

• Reduced terminal galactose on hinge region O-glycans of circulating IgA1 in IgAN.
• Hypothesized defect in B cell beta1,3 galactosyltransferase may cause this altered glycosylation.
• Altered glycosylation may impact IgA1 interactions with matrix proteins, receptors, and complement.

Conclusions:

• Altered hinge region O-glycosylation of IgA1 is a key feature in IgAN.
• This glycosylation defect may be a primary mechanism driving pIgA1 mesangial deposition.
• Physicochemical abnormalities of IgA1, specifically glycosylation, are implicated in IgAN pathogenesis and glomerular injury.